Havemeyer Place LP Takes Position in BioNTech SE Sponsored ADR $BNTX

Havemeyer Place LP acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 6,914 shares of the company’s stock, valued at approximately $658,000.

Several other hedge funds also recently modified their holdings of BNTX. Dodge & Cox increased its position in BioNTech by 315.7% during the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after buying an additional 2,769,654 shares during the last quarter. BNP Paribas Financial Markets increased its position in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after buying an additional 474,796 shares during the last quarter. Bank of America Corp DE increased its position in BioNTech by 344.4% during the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after buying an additional 444,332 shares during the last quarter. SG Americas Securities LLC increased its position in BioNTech by 1,664.6% during the fourth quarter. SG Americas Securities LLC now owns 365,333 shares of the company’s stock worth $34,780,000 after buying an additional 344,630 shares during the last quarter. Finally, Millennium Management LLC increased its position in BioNTech by 910.3% during the third quarter. Millennium Management LLC now owns 246,327 shares of the company’s stock worth $24,293,000 after buying an additional 276,727 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 2.9%

Shares of NASDAQ:BNTX opened at $85.50 on Tuesday. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market cap of $21.62 billion, a PE ratio of -14.54 and a beta of 1.33. The business has a 50 day moving average of $94.50 and a 200-day moving average of $98.75. The company has a quick ratio of 8.74, a current ratio of 8.80 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The firm had revenue of $1.06 billion for the quarter. As a group, equities research analysts forecast that BioNTech SE Sponsored ADR will post -4.66 earnings per share for the current year.

BioNTech announced that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that permits the company to buyback $1.00 billion in shares. This buyback authorization permits the company to buy up to 4.2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

BNTX has been the topic of a number of recent analyst reports. Canaccord Genuity Group lowered their price target on BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, May 23rd. Berenberg Bank lowered their price target on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. UBS Group raised BioNTech from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $117.00 to $135.00 in a research report on Wednesday, May 27th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of BioNTech in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and a consensus price target of $129.56.

Insider Activity

In other news, COO Sierk Poetting sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the completion of the sale, the chief operating officer owned 399,387 shares in the company, valued at $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by corporate insiders.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.